Next-Gen Weight-Loss Drugs Set To Up The Game From Ozempic And Mounjaro: WSJ
Portfolio Pulse from Benzinga Newsbot
The race to develop weight-loss drugs more potent than Ozempic and Mounjaro is heating up, with several contenders on the horizon. Novo Nordisk's Ozempic and Eli Lilly's Mounjaro have seen a surge in demand, and researchers are now focusing on next-generation weight-loss drugs. The success of these drugs has attracted new players like Amgen and Boehringer Ingelheim.
June 27, 2023 | 9:49 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Amgen's entry into the weight-loss drug market could lead to potential growth and a positive impact on its stock.
Amgen's entry into the rapidly expanding weight-loss drug market could lead to increased revenue and a positive impact on its stock as it competes with established players.
CONFIDENCE 80
IMPORTANCE 60
RELEVANCE 60
POSITIVE IMPACT
Eli Lilly's Mounjaro and experimental drug retatrutide could benefit from the growing weight-loss drug market, potentially boosting the company's stock.
Eli Lilly's Mounjaro has seen a surge in demand, and its experimental drug retatrutide shows promising results. This could lead to increased revenue and a positive impact on the company's stock.
CONFIDENCE 85
IMPORTANCE 70
RELEVANCE 80
NEGATIVE IMPACT
Novo Nordisk's Ozempic faces competition from next-generation weight-loss drugs, potentially impacting its market share.
As new weight-loss drugs are developed, they may outperform Ozempic, leading to a decrease in demand and market share for Novo Nordisk's product.
CONFIDENCE 85
IMPORTANCE 70
RELEVANCE 80